These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 18180487)
41. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending. Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749 [TBL] [Abstract][Full Text] [Related]
42. The Reach of the 340B Drug Pricing Program. Albrecht J; Mudahar S JAMA Dermatol; 2015 Sep; 151(9):923-4. PubMed ID: 25993384 [No Abstract] [Full Text] [Related]
43. Should the US allow prescription drug reimports from Canada? Pecorino P J Health Econ; 2002 Jul; 21(4):699-708. PubMed ID: 12146598 [TBL] [Abstract][Full Text] [Related]
44. Maximum allowable cost: can the government control drug costs? Smith MI; Wertheimer AI J Health Polit Policy Law; 1979; 4(2):155-75. PubMed ID: 385712 [TBL] [Abstract][Full Text] [Related]
45. Gift giving. Raszkowski RR S D J Med; 2002 Dec; 55(12):513-4. PubMed ID: 12516357 [No Abstract] [Full Text] [Related]
46. AMCP Guide to Pharmaceutical Payment Methods. AMCP Task Force on Drug Payment Methodologies J Manag Care Pharm; 2007 Oct; 13(8 Suppl C):S1-39. PubMed ID: 17970611 [TBL] [Abstract][Full Text] [Related]
47. Controlling spending for prescription drugs. Altman SH; Parks-Thomas C N Engl J Med; 2002 Mar; 346(11):855-6. PubMed ID: 11893800 [No Abstract] [Full Text] [Related]
48. Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology. American Society of Clinical Oncology J Oncol Pract; 2014 Jul; 10(4):259-63. PubMed ID: 24737877 [No Abstract] [Full Text] [Related]
49. Improving compliance through health care system and pharmaceutical company partnerships. Kozma CM Manag Care Interface; 2003 Mar; 16(3):29-30. PubMed ID: 12715409 [No Abstract] [Full Text] [Related]
50. Comparison of prescription drug costs in the United States and the United Kingdom, Part 1: statins. Jick H; Wilson A; Wiggins P; Chamberlin DP Pharmacotherapy; 2012 Jan; 32(1):1-6. PubMed ID: 22392823 [TBL] [Abstract][Full Text] [Related]
51. The pricing of statins and implications for Pharmaceutical Benefits Scheme expenditure. Clarke PM Med J Aust; 2013 Mar; 198(5):260. PubMed ID: 23496399 [No Abstract] [Full Text] [Related]
52. Pharmacy compliance with a prescription-drug discount program. Knapp KK; Law AV; Hitchman C N Engl J Med; 2002 Jul; 347(2):146-7; author reply 146-7. PubMed ID: 12110750 [No Abstract] [Full Text] [Related]
53. Experts' agency problems: evidence from the prescription drug market in Japan. Iizuka T Rand J Econ; 2007; 38(3):844-62. PubMed ID: 18478669 [TBL] [Abstract][Full Text] [Related]
54. Drug prices. AIDS Policy Law; 1996 Dec; 11(22):12. PubMed ID: 11364060 [TBL] [Abstract][Full Text] [Related]
55. Compulsory licensing and access to drugs. Stavropoulou C; Valletti T Eur J Health Econ; 2015 Jan; 16(1):83-94. PubMed ID: 24408475 [TBL] [Abstract][Full Text] [Related]
56. The impact of manufacturer coupon use in the statin market. Daugherty JB; Maciejewski ML; Farley JF J Manag Care Pharm; 2013; 19(9):765-72. PubMed ID: 24156645 [TBL] [Abstract][Full Text] [Related]
57. Drug companies' patient-assistance programs--helping patients or profits? Howard DH N Engl J Med; 2014 Jul; 371(2):97-9. PubMed ID: 25006717 [No Abstract] [Full Text] [Related]
59. Effects of Medicare Part D on drug affordability and use: Are seniors with prior high out-of-pocket drug spending affected more? Mott DA; Thorpe JM; Thorpe CT; Kreling DH; Gadkari AS Res Social Adm Pharm; 2010 Jun; 6(2):90-9. PubMed ID: 20511108 [TBL] [Abstract][Full Text] [Related]
60. New rules for US drug reimbursement. Bouchie A Nat Biotechnol; 2003 Oct; 21(10):1119-20. PubMed ID: 14520382 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]